Alterations in platelet function during aging: Clinical correlations with thromboinflammatory disease in older adults

Journal of the American Geriatrics Society

Volumn 62, Issue 3, 2014, Pages 529-535

  Mohebali, Donya ^a   Kaplan, David ^a   Carlisle, McKenzie ^b   Supiano, Mark A ^a   Rondina, Matthew T ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

aging; inflammation; monocyte; platelet; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOGEN; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR; THROMBOCYTE FACTOR 4; VON WILLEBRAND FACTOR;

AGING; ARTICLE; CEREBROVASCULAR ACCIDENT; HEART INFARCTION; HEMOSTASIS; HUMAN; INFLAMMATION; MONOCYTE; MONOTHERAPY; SEPSIS; SEPTIC SHOCK; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION; THROMBOSIS;

AGING; INFLAMMATION; MONOCYTE; PLATELET; THROMBOSIS;

AGED; AGING; BLOOD PLATELETS; HUMANS; INFLAMMATION; PLATELET AGGREGATION; THROMBOSIS;

EID: 84896404308     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.12700     Document Type: Article

References (56)

1. Kung HC, Hoyert DL, Xu J, et al. Deaths: Final data for 2005. Natl Vital Stat Rep 2008; 56: 1-120.
2. Stein PD, Hull RD, Kayali F, et al. Venous thromboembolism according to age: The impact of an aging population. Arch Intern Med 2004; 164: 2260-2265.
3. White RH,. The epidemiology of venous thromboembolism. Circulation 2003; 107: I4-I18.
4. Piazza G, Goldhaber SZ, Lessard DM, et al. Venous thromboembolism in patients with symptomatic atherosclerosis. Thromb Haemost 2011; 106: 1095-1102.
5. Martin GS, Mannino DM, Moss M,. The effect of age on the development and outcome of adult sepsis. Crit Care Med 2006; 34: 15-21.
6. Vieira-de-Abreu A, Rondina MT, Weyrich AS, et al. Inflammation. In:, Michelson AD, ed. Platelets, 3rd Ed. New York, NY: Elsevier, 2012, pp 733-766.
7. Anfossi G, Trovati M,. Role of catecholamines in platelet function: Pathophysiological and clinical significance. Eur J Clin Invest 1996; 26: 353-370.
8. Passacquale G, Vamadevan P, Pereira L, et al. Monocyte-platelet interaction induces a pro-inflammatory phenotype in circulating monocytes. PLoS ONE 2011; 6: e25595.
9. Franks ZG, Campbell RA, Weyrich AS, et al. Platelet-leukocyte interactions link inflammatory and thromboembolic events in ischemic stroke. Ann N Y Acad Sci 2010; 1207: 11-17.
10. Flick MJ, Du X, Witte DP, et al. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest 2004; 113: 1596-1606.
11. Lukasik M, Dworacki G, Kufel-Grabowska J, et al. Upregulation of CD40 ligand and enhanced monocyte-platelet aggregate formation are associated with worse clinical outcome after ischaemic stroke. Thromb Haemost 2012; 107: 346-355.
12. Rondina MT, Weyrich AS, Zimmerman GA,. Platelets as cellular effectors of inflammation in vascular diseases. Circ Res 2013; 112: 1506-1519.
13. Wolberg AS, Campbell RA,. Thrombin generation, fibrin clot formation and hemostasis. Transfus Apher Sci 2008; 38: 15-23.
14. Zahavi J, Jones NA, Leyton J, et al. Enhanced in vivo platelet "release reaction" in old healthy individuals. Thromb Res 1980; 17: 329-336.
15. Bastyr EJ 3rd, Kadrofske MM, Vinik AI,. Platelet activity and phosphoinositide turnover increase with advancing age. Am J Med 1990; 88: 601-606.
16. Jorgensen KA, Dyerberg J, Olesen AS, et al. Acetylsalicylic acid, bleeding time and age. Thromb Res 1980; 19: 799-805.
17. Reilly IA, FitzGerald GA,. Eicosenoid biosynthesis and platelet function with advancing age. Thromb Res 1986; 41: 545-554.
18. Johnson M, Ramey E, Ramwell PW,. Sex and age differences in human platelet aggregation. Nature 1975; 253: 355-357.
19. Sie P, Montagut J, Blanc M, et al. Evaluation of some platelet parameters in a group of elderly people. Thromb Haemost 1981; 45: 197-199.
20. Supiano MA, Hogikyan RV,. High affinity platelet alpha 2-adrenergic receptor density is decreased in older humans. J Gerontol 1993; 48: B173-B179.
21. Supiano MA, Linares OA, Halter JB, et al. Functional uncoupling of the platelet alpha 2-adrenergic receptor-adenylate cyclase complex in the elderly. J Clin Endocrinol Metab 1987; 64: 1160-1164.
22. Modesti PA, Fortini A, Abbate R, et al. Age related changes of platelet prostacyclin receptors in humans. Eur J Clin Invest 1985; 15: 204-208.
23. Chou TC, Yen MH, Li CY, et al. Alterations of nitric oxide synthase expression with aging and hypertension in rats. Hypertension 1998; 31: 643-648.
24. Loscalzo J,. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 2001; 88: 756-762.
25. Seidler S, Zimmermann HW, Bartneck M, et al. Age-dependent alterations of monocyte subsets and monocyte-related chemokine pathways in healthy adults. BMC Immunol 2010; 11: 30.
26. Fagiolo U, Cossarizza A, Scala E, et al. Increased cytokine production in mononuclear cells of healthy elderly people. Eur J Immunol 1993; 23: 2375-2378.
27. Ershler WB,. Interleukin-6: A cytokine for gerontologists. J Am Geriatr Soc 1993; 41: 176-181.
28. Ferrucci L, Corsi A, Lauretani F, et al. The origins of age-related proinflammatory state. Blood 2005; 105: 2294-2299.
29. Oleksowicz L, Mrowiec Z, Zuckerman D, et al. Platelet activation induced by interleukin-6: Evidence for a mechanism involving arachidonic acid metabolism. Thromb Haemost 1994; 72: 302-308.
30. Ziegler-Heitbrock L,. The CD14 + CD16 + blood monocytes: Their role in infection and inflammation. J Leukoc Biol 2007; 81: 584-592.
31. Fingerle G, Pforte A, Passlick B, et al. The novel subset of CD14 + /CD16 + blood monocytes is expanded in sepsis patients. Blood 1993; 82: 3170-3176.
32. Sadeghi HM, Schnelle JF, Thoma JK, et al. Phenotypic and functional characteristics of circulating monocytes of elderly persons. Exp Gerontol 1999; 34: 959-970.
33. Franchini M,. Hemostasis and aging. Crit Rev Oncol Hematol 2006; 60: 144-151.
34. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505.
35. Farrell DH,. γ' Fibrinogen as a novel marker of thrombotic disease. Clin Chem Lab Med 2012; 50: 1903-1909.
36. Conlan MG, Folsom AR, Finch A, et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993; 70: 380-385.
37. Coppola R, Mari D, Lattuada A, et al. Von Willebrand factor in Italian centenarians. Haematologica 2003; 88: 39-43.
38. Tracy RP, Arnold AM, Ettinger W, et al. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: Results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1999; 19: 1776-1783.
39. Mehta J, Mehta P, Lawson D, et al. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: Correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 1987; 9: 263-268.
40. Nylander M, Osman A, Ramstrom S, et al. The role of thrombin receptors PAR1 and PAR4 for PAI-1 storage, synthesis and secretion by human platelets. Thromb Res 2012; 129: e51-e58.
41. Eren M, Painter CA, Atkinson JB, et al. Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation 2002; 106: 491-496.
42. Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e601S-e636S.
43. Klinkhardt U, Bauersachs R, Adams J, et al. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther 2003; 73: 232-241.
44. Storey RF, Judge HM, Wilcox RG, et al. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost 2002; 88: 488-494.
45. Committee CS,. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-1339.
46. Weyrich AS, Denis MM, Kuhlmann-Eyre JR, et al. Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates. Circulation 2005; 111: 633-642.
47. Group ES, Halkes PH, van Gijn J, et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomised controlled trial. Lancet 2006; 367: 1665-1673.
48. Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359: 1238-1251.
49. Yende S, Tuomanen EI, Wunderink R, et al. Preinfection systemic inflammatory markers and risk of hospitalization due to pneumonia. Am J Respir Crit Care Med 2005; 172: 1440-1446.
50. Hagiwara S, Iwasaka H, Hasegawa A, et al. Adenosine diphosphate receptor antagonist clopidogrel sulfate attenuates LPS-induced systemic inflammation in a rat model. Shock 2011; 35: 289-292.
51. Zarbock A, Singbartl K, Ley K,. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest 2006; 116: 3211-3219.
52. Looney MR, Nguyen JX, Hu Y, et al. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest 2009; 119: 3450-3461.
53. Erlich JM, Talmor DS, Cartin-Ceba R, et al. Prehospitalization antiplatelet therapy is associated with a reduced incidence of acute lung injury: A population-based cohort study. Chest 2011; 139: 289-295.
54. Winning J, Neumann J, Kohl M, et al. Antiplatelet drugs and outcome in mixed admissions to an intensive care unit. Crit Care Med 2010; 38: 32-37.
55. Harr JN, Moore EE, Johnson J, et al. Antiplatelet therapy is associated with decreased transfusion-associated risk of lung dysfunction, multiple organ failure, and mortality in trauma patients. Crit Care Med 2013; 41: 399-404.
56. Kor DJ, Talmor DS, Banner-Goodspeed VM, et al. Lung Injury Prevention with Aspirin (LIPS-A): A protocol for a multicentre randomised clinical trial in medical patients at high risk of acute lung injury. BMJ 2012; 2: e001606.